Literature DB >> 11747598

Helper plasmids for production of HIV-1-derived vectors.

M Fuller1, D S Anson.   

Abstract

Vectors derived from human immunodeficiency virus type 1 (HIV-1) appear an attractive option for many gene therapy applications. This is due to their ability to transduce noncycling cell populations and to integrate their genome into the host cell chromosome, resulting in the stable genetic modification of the transduced cell. These properties have permitted the direct in vivo transduction of several tissues, including the central nervous system, retina, and liver. However, the pathogenic nature of HIV-1 has raised considerable concerns about the safety of such vector systems. To help address these concerns, we have expressed each of the primary transcriptional units encoding trans functions relevant for vector production in individual plasmid constructs. The gag-pol gene sequence was codon-optimized for expression in mammalian cells resulting in high level Rev/Rev-response element (RRE)-independent expression. Codon optimization of gag-pol also reduces sequence homology with vectors containing gag gene sequences, which results in reduced transfer of biologically active gag-pol sequences to transduced cells. Furthermore, the vif reading frame overlapping the 3' end of the pol coding sequence is destroyed by codon optimization. We have also shown that the Gag and Gag-Pol polyproteins can be efficiently expressed from separate transcriptional units. This has enabled the removal of a cis-acting viral element, the gag-pol translational frameshift sequence, from the vector/packaging system and prevents detectable transfer of biologically active sequences equivalent to the gag-pol gene to transduced cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747598     DOI: 10.1089/10430340152677421

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

Review 1.  Codon-optimized reading frames facilitate high-level expression of the HIV-1 minor proteins.

Authors:  D S Anson; K R Dunning
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

2.  Analysis of partial recombinants in lentiviral vector preparations.

Authors:  Seraphin Kuate; Michael P Marino; Jakob Reiser
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

3.  Soluble Expression and Catalytic Properties of Codon-Optimized Recombinant Bromelain from MD2 Pineapple in Escherichia coli.

Authors:  Rafida Razali; Cahyo Budiman; Khairul Azfar Kamaruzaman; Vijay Kumar Subbiah
Journal:  Protein J       Date:  2021-03-13       Impact factor: 2.371

4.  Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Authors:  Simon H Bridge; Sally A Sharpe; Mike J Dennis; Stuart D Dowall; Brian Getty; Donald S Anson; Michael A Skinner; James P Stewart; Tom J Blanchard
Journal:  Virol J       Date:  2011-09-07       Impact factor: 4.099

5.  Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.

Authors:  Donald S Anson; Chantelle McIntyre; Belinda Thomas; Rachel Koldej; Enzo Ranieri; Ainslie Roberts; Peter R Clements; Kylie Dunning; Sharon Byers
Journal:  Genet Vaccines Ther       Date:  2007-01-16

Review 6.  Phoenix rising: gene therapy makes a comeback.

Authors:  Maria P Limberis
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-05-23       Impact factor: 3.848

7.  Design of a trans protease lentiviral packaging system that produces high titer virus.

Authors:  Karen A Westerman; Zhujun Ao; Eric A Cohen; Philippe Leboulch
Journal:  Retrovirology       Date:  2007-12-28       Impact factor: 4.602

8.  The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery.

Authors:  Donald S Anson
Journal:  Genet Vaccines Ther       Date:  2004-08-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.